Company profile: Cardiac Insight
1.1 - Company Overview
Company description
- Provider of body-worn ECG sensing technology, including Cardea SOLO, a wearable ambulatory ECG for up to seven days of continuous heart rhythm monitoring with in-office data analysis, and Cardea 20/20 ECG, an automated 12-lead ECG system designed to detect cardiovascular issues in young athletes using International Consensus Criteria.
Products and services
- Cardea 20/20 ECG: An automated 12-lead ECG system architected to detect cardiovascular issues in young athletes using International Consensus Criteria for assessments, standards-aligned
- Cardea SOLO: A wearable ambulatory ECG device engineered for continuous heart rhythm monitoring over seven days with facilitated in-office data analysis, ambulatory-grade
- Body-worn ECG sensing technology: Cardiac Insight delivers wearable electrocardiogram sensing technology for on-body ECG data capture, body-worn
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cardiac Insight
Celladon
HQ: United States
Website
- Description: Provider of biotechnology focused on developing molecular therapies for the treatment of heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celladon company profile →
R3 Vascular
HQ: United States
Website
- Description: Provider of medical devices for peripheral artery disease, including the MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS), which maintains vessel support, delivers sirolimus to prevent restenosis, and gradually resorbs into tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full R3 Vascular company profile →
JenaValve
HQ: United States
Website
- Description: Provider of transcatheter heart valve solutions, including the Trilogy Heart Valve System for TAVR to treat severe aortic regurgitation or stenosis, featuring a self-expanding nitinol frame and locator technology for precise placement. Offers the Trilogy Valve for secure anchoring without calcium, a Delivery System for precise deployment, and an 85cm pre-shaped Introducer Sheath for safe vascular access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JenaValve company profile →
Portola Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics, discovering and developing treatments for acute and chronic cardiovascular and autoimmune/inflammatory diseases, including PRT054021, an oral factor Xa inhibitor for prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Portola Pharmaceuticals company profile →
Kardium
HQ: Canada
Website
- Description: Provider of the Globe Pulsed Field System for the diagnosis and treatment of atrial fibrillation, integrating pulmonary vein isolation, high-definition mapping, and atrial ablation in a single catheter. Offers the Globe PF Mapping and Ablation System with a 122-electrode catheter, the Globe Catheter (30 mm spherical array, 122 electrodes), and the PULSAR clinical study evaluating safety and effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kardium company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cardiac Insight
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cardiac Insight
2.2 - Growth funds investing in similar companies to Cardiac Insight
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cardiac Insight
4.2 - Public trading comparable groups for Cardiac Insight
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →